On August 4, 2026, the U.S. pharma sector received major news: Merck & Co., Inc. (NYSE: MRK) announced that MK-8891, its AI-discovered lung cancer candidate, had been granted Breakthrough Therapy designation by the U.S. FDA. The board also approved raising the quarterly dividend from $0.70 to $0.75 per share, an increase of about 7.1%, marking the 12th consecutive year of dividend increases. Following the announcement, Merck's stock rose as much as 5.2% intraday, lifting the S&P 500 health care sector, and high-dividend pharma stocks once again became a market focus.
AI Drug Discovery Milestone: From Target Discovery to Faster Clinical Development
MK-8891 is the first candidate from Merck's internal AI drug discovery platform "Atlas" to reach late-stage clinical development. It targets patients with non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation. By using AI to predict protein three-dimensional structures and virtual screening of a billion-compound library, the drug shortened the preclinical research cycle from the industry average of 4-5 years to 2.8 years, significantly improving R&D efficiency.
In a conference call, a Merck Research Laboratories executive said: "This Breakthrough Therapy designation not only validates the therapeutic potential of MK-8891 but also marks the transition of AI-driven drug discovery from concept to tangible output. We will continue to expand the Atlas platform's application in oncology, metabolism, neuroscience, and other areas."
12 Consecutive Years of Dividend Increases: The "Ballast Stone" of the High-Dividend Strategy
In addition to the progress in its innovative drug pipeline, Merck's shareholder return policy also surprised the market. The company announced a quarterly cash dividend increase to $0.75 per share, implying an annualized dividend yield of approximately 3.4% at the current share price, higher than the median level of S&P 500 constituents. Since 2015, Merck has raised its dividend for 12 consecutive years, with a cumulative increase of more than 80%, earning it a reputation as a "dividend stalwart" in the U.S. pharma sector.
Notably, Merck's dividend payout ratio remains in a healthy range of about 45%, supported by ample free cash flow. Its second-quarter 2026 earnings report showed adjusted earnings per share up 12% year over year, driven mainly by continued strong global sales of the oncology drug Keytruda and smooth market expansion of its newly approved cardiovascular drug.
"Innovation + Dividend" Resonance: A New Investment Logic for Pharma Stocks
Merck's case is not isolated. In recent years, major U.S. drugmakers have increased R&D spending while also rewarding shareholders through dividends and buybacks. Data shows that more than 80% of S&P 500 health care components have paid dividends for five consecutive years, with many raising them steadily each year. This combination of growth and defensive characteristics makes the pharma sector a core allocation for institutional investors amid interest rate fluctuations and heightened macroeconomic uncertainty.
A health care fund manager at BlackRock commented: "AI technology is reshaping the R&D balance sheet of drugmakers. Over the past decade, large pharma companies faced patent cliffs and declining R&D returns. AI-enabled drug discovery tools can lower costs and improve success rates, providing more sustainable cash flow to support high dividends."
AI Drug Discovery Accelerates Industry Reshuffling
The AI drug discovery track saw an investment boom in 2026. According to incomplete statistics, global financing in the AI drug discovery field exceeded $12 billion in the first half of this year, up 45% year over year. Besides Merck, giants such as Pfizer, Novartis, and Johnson & Johnson have also stepped up investment in AI platforms or quickly acquired technical capabilities through acquisitions of AI startups. Last month, Pfizer announced a roughly $10 billion acquisition of an emerging AI drug discovery company, drawing market attention.
However, some analysts caution that the long-term value of AI drug discovery still depends on clinical validation. Most AI-discovered drugs are currently in early or mid-stage development, and whether they will ultimately receive FDA approval remains uncertain. While chasing the AI concept, investors should also pay close attention to drugmakers' cash dividend capacity and the quality of their pipeline.
Pharma Dividend ETFs: Accessing Both U.S. High-Dividend and Innovative Drug Tracks
For ordinary investors, participating in the pharma dividend rally through ETFs is a more convenient approach. Several U.S. ETFs focus on health care high dividends; for example, the Schwab U.S. Dividend Equity ETF (SCHD) has a health care weighting of over 15%, and the Vanguard Dividend Appreciation ETF (VIG) also holds multiple pharma blue chips. In addition, broad health care ETFs such as XLV include major drugmakers like Merck, Johnson & Johnson, and Pfizer, offering both upside from innovative drug rebounds and stable dividend income.
Since this week, health care ETFs have seen notable net inflows, boosted by stocks like Merck. According to ETF.com data, XLV recorded net inflows of approximately $1.8 billion over the past five trading days, a six-month high. Analysts believe that as AI drug discovery moves from concept to reality and traditional drugmakers continue raising dividends, the U.S. pharma dividend rally is likely to persist.
Risk Warning and Outlook
Despite the positive outlook for the pharma sector, investors should remain vigilant about risks such as drug approval failures, medical price reductions, and patent expirations. Merck's core Keytruda patents are expected to expire around 2030, when it will face biosimilar competition. Whether the company can smoothly transition to its AI-driven pipeline will be key to growth over the next several years. Meanwhile, if U.S. regulatory policies take a tougher stance on drug pricing, drugmakers' profit margins could be affected.
Overall, Merck's dual good news of innovative drugs and high dividends provides a typical case for evaluating the investment value of dividend-paying pharma stocks. With AI technology, traditional drugmakers are gaining new vitality, while consistent shareholder returns offer reliable downside protection for long-term investors.
